Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy
Rhea-AI Filing Summary
Evogene Ltd. director Leon Recanati purchased 800,000 Ordinary Shares on August 4, 2026 in multiple transactions at a weighted average price of $0.50 per share, increasing his direct ownership to 883,886 Ordinary Shares. He also reports existing stock option positions for informational purposes.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 800,000 shares
Net Buy
12 txns
Insider
RECANATI LEON
Role
Director
Bought
800,000 shs ($400K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Shares F1 | 800,000 | $0.50 | $400K |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F2, F3 | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 883,886 shares (Direct);
Stock Option (right to buy) — 11,200 shares (Direct)
Footnotes (3)
- F1. The price reported in column 4 of this row is a weighted average price. These shares were purchased in multiple transactions on August 4, 2026 within a range of prices per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
- F2. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F3. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.
Key Figures
Shares purchased: 800,000 Ordinary Shares
Weighted average price: $0.5000 per share
Direct holdings after purchase: 883,886 Ordinary Shares
+4 more
7 metrics
Shares purchased
800,000 Ordinary Shares
Non-derivative purchase on August 4, 2026
Weighted average price
$0.5000 per share
Price for 800,000 Ordinary Shares purchased on August 4, 2026
Direct holdings after purchase
883,886 Ordinary Shares
Direct ownership following reported transactions on August 4, 2026
Option exercise price
$72.4600 per share
Stock option on 250 Ordinary Shares expiring 2026-05-18
Option exercise price
$28.6200 per share
Stock option on 1,800 Ordinary Shares expiring 2031-09-01
Option exercise price
$10.5000 per share
Stock option on 1,800 Ordinary Shares expiring 2032-09-15
Option exercise price
$1.2900 per share
Stock option on 2,500 Ordinary Shares expiring 2035-08-18
Key Terms
Ordinary Shares, Stock Option (right to buy, weighted average price, grant date, +1 more
5 terms
Stock Option (right to buy financial
"security title listed as "Stock Option (right to buy)" over Ordinary Shares"
weighted average price financial
"The price reported in column 4 of this row is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
grant date financial
"fully vested on the one-year anniversary of the August 18, 2025 grant date."
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vest equally on a quarterly basis financial
"The options reported in this row vest equally on a quarterly basis"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Does the Evogene (EVGN) insider report include any stock option holdings?
Yes. The report lists several Stock Options (right to buy) over Evogene Ordinary Shares, with exercise prices ranging from $72.4600 down to $1.2900. These option entries are included for informational purposes only and were not newly transacted.
Was the Evogene (EVGN) insider purchase made under a Rule 10b5-1 trading plan?
The disclosure indicates the Rule 10b5-1 plan checkbox is not marked, so the reported trades are not affirmed as being made under a pre-arranged Rule 10b5-1 trading plan. No footnote describes any such plan arrangement for these purchases.
What derivative exposure to Evogene (EVGN) does Leon Recanati report?
He reports multiple stock options over Evogene Ordinary Shares, including options on 2,500 shares at $1.2900 per share and several 1,800-share options at higher exercise prices, all held directly and shown as existing positions rather than new transactions.